-
Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin
- Back
Metadata
Document Title
Distal Effect of Amino Acid Substitutions in CYP2C9 Polymorphic Variants Causes Differences in Interatomic Interactions against (S)-Warfarin
Author
Lertkiatmongkol P, Assawamakin A, White G, Chopra G, Rongnoparut P, Samudrala R, Tongsima S
Name from Authors Collection
Affiliations
Mahidol University; National Science & Technology Development Agency - Thailand; National Center Genetic Engineering & Biotechnology (BIOTEC); University of Washington; University of Washington Seattle; Mahidol University; University of California System; University of California San Francisco
Type
Article
Source Title
PLOS ONE
Year
2013
Volume
8
Issue
9
Open Access
Green Published, Green Submitted, gold
Publisher
PUBLIC LIBRARY SCIENCE
DOI
10.1371/journal.pone.0074053
Format
Abstract
Cytochrome P450 2C9 (CYP2C9) is crucial in excretion of commonly prescribed drugs. However, changes in metabolic activity caused by CYP2C9 polymorphisms inevitably result in adverse drug effects. CYP2C9*2 and *3 are prevalent in Caucasian populations whereas CYP2C9*13 is remarkable in Asian populations. Single amino acid substitutions caused by these mutations are located outside catalytic cavity but affect kinetic activities of mutants compared to wild-type enzyme. To relate distal effects of these mutations and defective drug metabolisms, simulations of CYP2C9 binding to anti-coagulant (S)-warfarin were performed as a system model. Representative (S)-warfarin-bound forms of wild-type and mutants were sorted and assessed through knowledge-based scoring function. Interatomic interactions towards (S)-warfarin were predicted to be less favorable in mutant structures in correlation with larger distance between hydroxylation site of (S)-warfarin and reactive oxyferryl heme than wild-type structure. Using computational approach could delineate complication of CYP polymorphism in management of drug therapy.
Industrial Classification
Knowledge Taxonomy Level 1
Knowledge Taxonomy Level 2
Knowledge Taxonomy Level 3
Funding Sponsor
Office of the Higher Education Commission; Mahidol University under the National Research Universities Initiative; Thailand Research Fund (TRF) [RSA5480026]; Research Chair Grant National Science and Technology Development Agency; NIH Director's Pioneer Award; NATIONAL LIBRARY OF MEDICINE [DP1LM011509] Funding Source: NIH RePORTER
License
CC BY
Rights
Authors
Publication Source
WOS